- Home
- NOTE vs PROK Comparison
NOTE vs PROK Comparison
Compare NOTE & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTE
- PROK
- Stock Information
- Founded
- NOTE 2013
- PROK 2015
- Country
- NOTE United States
- PROK United States
- Employees
- NOTE N/A
- PROK N/A
- Industry
- NOTE EDP Services
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NOTE Technology
- PROK Health Care
- Exchange
- NOTE Nasdaq
- PROK Nasdaq
- Market Cap
- NOTE 83.1M
- PROK 85.5M
- IPO Year
- NOTE N/A
- PROK N/A
- Fundamental
- Price
- NOTE $0.69
- PROK $4.74
- Analyst Decision
- NOTE Strong Buy
- PROK Buy
- Analyst Count
- NOTE 6
- PROK 4
- Target Price
- NOTE $2.63
- PROK $5.33
- AVG Volume (30 Days)
- NOTE 3.4M
- PROK 33.1M
- Earning Date
- NOTE 08-07-2025
- PROK 08-08-2025
- Dividend Yield
- NOTE N/A
- PROK N/A
- EPS Growth
- NOTE N/A
- PROK N/A
- EPS
- NOTE N/A
- PROK N/A
- Revenue
- NOTE $115,665,000.00
- PROK $306,000.00
- Revenue This Year
- NOTE N/A
- PROK $54.34
- Revenue Next Year
- NOTE $41.14
- PROK N/A
- P/E Ratio
- NOTE N/A
- PROK N/A
- Revenue Growth
- NOTE N/A
- PROK N/A
- 52 Week Low
- NOTE $0.48
- PROK $0.46
- 52 Week High
- NOTE $2.07
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- NOTE 61.52
- PROK 92.14
- Support Level
- NOTE $0.66
- PROK $0.54
- Resistance Level
- NOTE $0.84
- PROK $7.13
- Average True Range (ATR)
- NOTE 0.07
- PROK 0.62
- MACD
- NOTE 0.03
- PROK 0.47
- Stochastic Oscillator
- NOTE 68.32
- PROK 68.59
About NOTE FiscalNote Holdings Inc.
FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.